Shares of Tilray Inc (NASDAQ:TLRY – Get Free Report) traded down 1.1% on Tuesday . The company traded as low as $1.68 and last traded at $1.69. 5,634,338 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 25,361,375 shares. The stock had previously closed at $1.71.
Tilray Price Performance
The company has a market cap of $1.30 billion, a P/E ratio of -3.82 and a beta of 2.19. The firm’s 50-day moving average is $1.82 and its two-hundred day moving average is $1.88. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.27 and a quick ratio of 1.42.
Tilray (NASDAQ:TLRY – Get Free Report) last issued its quarterly earnings data on Monday, July 29th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The business had revenue of $229.90 million during the quarter, compared to analysts’ expectations of $226.20 million. Tilray had a negative return on equity of 2.63% and a negative net margin of 30.26%. The business’s quarterly revenue was up 24.8% on a year-over-year basis. During the same period in the previous year, the business earned ($0.15) earnings per share. Analysts anticipate that Tilray Inc will post -0.12 earnings per share for the current year.
Institutional Investors Weigh In On Tilray
About Tilray
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Further Reading
- Five stocks we like better than Tilray
- Stock Sentiment Analysis: How it Works
- Emerging Markets: What They Are and Why They Matter
- Investing In Automotive Stocks
- Recession or Not, These 3 Stocks Are Winners
- Top Biotech Stocks: Exploring Innovation Opportunities
- Why NVIDIA Is More of a Screaming Buy Than Ever
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.